SEC Filings

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. We leverage our deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer.

Our innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression into proof-of concept trials in several indications following encouraging single-agent activity in Phase 1.

iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

For investors

Discover more about iTeos Therapeutics, our science, and our high potential for investment.

SEC Filings

Filing date Form Description Filing Group View
3

Initial filing by director officer or owner of more than ten percent.

3,4,5
View HTML
3

Initial filing by director officer or owner of more than ten percent.

3,4,5
View HTML
3

Initial filing by director officer or owner of more than ten percent.

3,4,5
View HTML
3

Initial filing by director officer or owner of more than ten percent.

3,4,5
View HTML
3

Initial filing by director officer or owner of more than ten percent.

3,4,5
View HTML
3

Initial filing by director officer or owner of more than ten percent.

3,4,5
View HTML
3

Initial filing by director officer or owner of more than ten percent.

3,4,5
View HTML
3

Initial filing by director officer or owner of more than ten percent.

3,4,5
View HTML
S-1MEF

Registration of up to an additional 20% of securities for any offering registered on an S-1

Registration Statements
View HTML
EFFECT

EFFECT

Other
View HTML

Data provided by Kaleidoscope.

Cancer Cells graphics

At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.

Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.

Driven by a culture of scientific innovation, collaboration and excellence, together we discover and deliver breakthrough immunotherapies to improve and extend the lives of people with cancer.